<h1 itemprop="aspect"> <strong>Xigris Side Effects</strong></h1><h1><a href="http://www.bad-drug.net/wp-content/uploads/2012/10/xigris.jpg?1df917"><img class=" wp-image-4525 alignright" alt="xigris injection package" src="http://www.bad-drug.net/wp-content/uploads/2012/10/xigris.jpg?1df917" width="175" height="175" pagespeed_url_hash="4071079914" onload="pagespeed.CriticalImages.checkImageForCriticality(this);"/></a>Serious Side Effects of Xigris</h1> <strong>Patients experiencing these symptoms should seek medical attention</strong><ul><li>Serious<strong> internal bleeding</strong> including<strong> intracranial hemorrhag</strong>e and bleeding in the chest</li><li>Stomach pain due to<strong> gastrointestinal and intra-abdominal bleeding</strong></li><li><strong>Severe allergic reactions</strong> including black/bloody stools, pink/red urine, slurred speech, and vision problems</li><li><strong>Low red blood cell counts</strong> that require 3 or more units of packed red blood cells per day for 2 days</li><li>Trouble breathing and easy bruising, with weakness and confusion</li></ul></div><div class="v" id="tab2" ><h2 itemprop="aspect"> <strong> Warnings & Recalls for Xigris </strong></h2><h1>Xigris Withdrawal from market</h1> In October of 2011, Lilly agreed to <strong>voluntarily withdraw</strong> Xigris from the market because studies failed to show benefits for patients being administered the drug.Xigris can cause <strong>severe bleeding</strong> and for this reason guidelines have been set for its use. Xigris should only be administered by intensive care units where close monitoring of the patients can occur, and it should only be administered by a medical professional capable of weighing the true benefits and risks of Xigris.For more information click <a href="http://www.fda.gov/Drugs/DrugSafety/ucm277114.htm" target="_blank" rel="nofollow">here</a>.&nbsp;<h2>Other warnings</h2> Patients who have <strong>organ dysfunction</strong> from sepsis and have undergone recent surgery may have a<strong> higher chance of death</strong> on Xigris.Patients on Xigris should be on bed rest and should inform their doctor of any other medical care/surgery.Xigris may effect lab tests for partial thromboplastin time and coagulation so patients on the drug should be advised.Xigris <strong>SHOULD NOT be used</strong> in:<ul><li>children</li><li>those who are allergic to any ingredients in Xigris (drotrecogin alfa, sucrose, sodium chloride, citrate, sodium citrate, hydrochloric acid and sodium hydroxide)</li><li>those who have any internal bleeding or brain tumors</li><li>anyone who has had a stroke within the last 3 months</li><li>persons who have had brain or spinal surgery including severe head trauma within the last 2 months</li><li>those who have been traumatically hurt with a risk of life-threatening bleeding</li><li>anyone using an epidural catheter</li><li>those with known mass lesions</li><li>anyone who is hypersensitive to Xigris or any ingredient of Xigris</li></ul><div><strong>Before using Xigris</strong> patients should let their physician know if they are in/have any of the following situations:</div><div><ul><li>taking herbal and dietary supplements</li><li>any allergies</li><li>bleeding/blood clotting problems</li><li>low platelet levels</li><li>high risk of bleeding including stomach bleeding, aneurysms</li><li>kidney or liver problems</li><li>HIV infections</li><li>organ transplants and ulcers</li><li>anyone who has had any recent surgery or stroke.</li></ul></div> Those who fall under the following categories are <strong>at risk for increased bleeding complications</strong> while on Xigris:<ul><li>those on concurrent therapeutic heparin of 15 kg/h or greater</li><li>low platelet count</li><li>gastrointestinal bleeding within 6 weeks</li><li>those given thrombolytic therapy within 3 days, those on oral anticoagulants, aspirin or platelet inhibitors within 7 days</li><li>those with known bleeding problems</li><li>chronic hepatic disease</li><li>persons with an HIV infection with low CD4 counts</li><li>anyone with a prothrombin time reading of less than 3.0</li><li>those with bleeding hazards at unreachable locations</li><li>persons who have previously received Xigris.</li></ul><h2><strong>Contraindications</strong></h2> Include anticoagulants, glycoprotein inhibitors, heparin, platelet inhibitors, salicylates and tissue plasminogen activators. Drugs that affect hemostasis (the stoppage of blood flow) like aspirin, warfarin and clopidogrel, should be used with caution.Ibuprofen, acetaminophen, naproxen, and Vitamin E are also known to interfere with Xigris.<div><h2><strong>Xigris and Pregnancy</strong></h2> It is <strong>unknown</strong> if Xigris will cause fetal harm, therefore patients should consult their doctor to weigh the benefits and risks of using this drug while pregnant.It is also unknown whether Xigris will pass through breast milk, therefore nursing mothers are advised <strong>not</strong> to breast feed.</div></div><div class="v" id="tab3" ><h2 itemprop="aspect"> <strong> Xigris Treatment and Use </strong></h2><h2>What is Xigris?</h2><p><strong>Xigris</strong> |drotrecogin alfa is an<strong> intravenous injection</strong> produced by Lilly used to treat the bacterial infection of the blood known as <strong>sepsis</strong>. In October 0f 2011, Xigris was <strong>withdrawn</strong> from the market after studies showed little to no efficacy in the treatment of sepsis.</p><h2>How does Xigris work?</h2><p>The drug Xigris is a human activated Protein C that <strong>slow down blood clotting</strong> by inhibiting facts Va and VIIIa (blood clotting proteins) and permits profibrinolytic activity (the prevention and breakdown of blood clots). Xigris also exerts<strong> anti-inflammatory responses</strong> by blocking leukocytes (white blood cells) adhering to an infection site, and limits inflammation.</p><h2>Dosage information</h2><p>Xigris should be administered <strong>intravenously</strong> by a medial professional at an infusion rate of<strong> 24 mcg/kg/hr</strong> and based on total body weight for the duration of 96 hours.</p></div><div class="v" id="tab4" ><h2 itemprop="aspect"> Other Names for Xigris</h2> <strong>Brand name</strong>:<br/><ul><br/><li>Xigris D</li><br/></ul><br/> <strong>Generic name</strong>:<br/><ul><br/><li>Drotrecogin alfa (activated).</li><br/></ul></div><div class="v" id="tab5" ><h2 itemprop="aspect"> <strong> Lawsuits & Legal Information for Xigris </strong></h2>